New Releases from NCBI BookshelfPembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer.Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer.